Literature DB >> 10203064

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.

L J Esserman1, T Lopez, R Montes, L N Bald, B M Fendly, M J Campbell.   

Abstract

The HER2/neu oncogene product, p185(HER2/neu), is overexpressed on the surface of many human breast cancers. Strains of transgenic mice have been developed that express the rat neu oncogene in mammary epithelial cells and develop spontaneous mammary tumors that overexpress p185neu. This model provides an ideal system for testing interventions to prevent tumor development. In this study, we immunized neu-transgenic mice with a vaccine consisting of the extracellular domain of p185neu (NeuECD). Immunized mice developed Neu-specific humoral immune responses, as measured by circulating anti-Neu antibodies in their sera, and cellular immune responses, as measured by lymphocyte proliferation to NeuECD in vitro. In addition, the subsequent development of mammary tumors was significantly lower in immunized mice than in controls and vaccine treatment was associated with a significant increase in median survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203064     DOI: 10.1007/s002620050539

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

2.  Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model.

Authors:  Mojgan Ghaedi; Forough Golsaz-Shirazi; Tannaz Bahadori; Jalal Khoshnoodi; Sahar Mortezagholi; Mahmood Jeddi-Tehrani; Mohammad Mehdi Amiri; Fazel Shokri
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

3.  Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine.

Authors:  Yunping Luo; He Zhou; Masato Mizutani; Noriko Mizutani; Ralph A Reisfeld; Rong Xiang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

4.  Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Authors:  Michael J Campbell; Wendy S Wollish; Margaret Lobo; Laura J Esserman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

Review 5.  Pre-clinical applications of transgenic mouse mammary cancer models.

Authors:  C J Kavanaugh; K V Desai; A Calvo; P H Brown; C Couldrey; R Lubet; J E Green
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

6.  Preclinical HER-2 Vaccines: From Rodent to Human HER-2.

Authors:  Pier-Luigi Lollini; Carla De Giovanni; Patrizia Nanni
Journal:  Front Oncol       Date:  2013-06-10       Impact factor: 6.244

7.  Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Authors:  P Nanni; G Nicoletti; C De Giovanni; L Landuzzi; E Di Carlo; F Cavallo; S M Pupa; I Rossi; M P Colombo; C Ricci; A Astolfi; P Musiani; G Forni; P L Lollini
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

8.  Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.

Authors:  C T Siegel; K Schreiber; S C Meredith; G B Beck-Engeser; D W Lancki; C A Lazarski; Y X Fu; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.